Selective modulation of y-secretase processing through substrate binding
Selective modulation of y-secretase processing through substrate binding
批准号:
7662735
负责人:
THOMAS L KUKAR
金额:
$9.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-04-01 至 2011-03-31
关键词:
Abeta synthesisAddressAdverse effectsAffectAlzheimer&aposs DiseaseAmino AcidsAmyloid beta-Protein PrecursorAnti-Inflammatory AgentsAnti-inflammatoryBindingBiologyC-terminalChemicalsCleaved cellClipComplexCrystallographyDataDementiaDevelopmentDimerizationElderlyEnzymesEventFutureInstructionInvestigationLabelLeadLinkMammalian CellMapsMass Spectrum AnalysisMembraneMembrane ProteinsMentorsMethodsMolecular BiologyMutagenesisNatural regenerationNotch Signaling PathwayPathway interactionsPatternPeptide HydrolasesPeptidesPharmaceutical PreparationsPhasePlayPositioning AttributePrincipal InvestigatorProcessProductionProtein BiochemistryProtein CProteolysisReportingResearchResearch PersonnelResolutionRiskRoleSignal PathwaySignal TransductionSiteSpecificitySystemTechniquesTestingTherapeuticToxic effectTrainingWorkamyloid precursor protein processingbasecareercrosslinkdesigngamma secretaseimprovedin vivoinhibitor/antagonistinsightnotch proteinnovelpresenilinpreventprogramsprotective effectprotein protein interactionresearch studyrhosecretasesmall moleculetherapeutic target
中文摘要
项目简介(由申请人提供):项目主任/首席研究员(最后,第一,中):Kukar, Thomas L.项目总结(见说明):大量证据支持这一假设,即选择性靶向A¿42是预防和可能治疗老年痴呆症(AD)的理想治疗策略。一类化合物叫做?分泌酶调节剂(GSMs)由于能够选择性地改变A¿42水平而被用作阿尔茨海默病的治疗药物。第一批发现的GSMs是某些非甾体抗炎药(NSAIDs),它们已被证明可以选择性地降低A¿42,而不会全面抑制APR加工。由于整个gsm最小限度地改变了总β的产生,而是改变了γ分泌酶的切割位点。gsm的作用机制尚未得到最终证实,对其活性的不同解释包括:1)与?-分泌酶2)抑制Rho-ROCK信号通路3)早早素构象改变或4)降低APR二聚化。我们最近发现,使用新型GSM光亲和探针,这些药物不标记y-分泌酶,而是通过与底物APP结合来调节裂解。我们假设GSM结合APR改变了APP- ctf在膜中的位置,从而改变了-分泌酶的裂解。这一假设将通过以下具体目标进行验证:1)利用分子生物学和蛋白质生物化学的结合,研究GSMs靶向底物如何产生a¿切割模式的转变;2)确定GSMs影响APP蛋白水解的特异性?3)检测非天然氨基酸是否可以用于研究-分泌酶对APP-CTF¿的蛋白水解作用。目标1和职业/技术培训将在指导阶段进行,这将促进目标2和目标3在独立阶段的执行。这些研究应该为非甾体抗炎药和其他gsm改变A -裂解的机制以及它们如何在体内发挥保护作用提供更多的见解。这项工作还将指导未来设计更有效的gsm的努力,这些gsm将作为化学探针用于了解?分泌酶和阿尔茨海默病的潜在疗法。相关性(见说明):阿尔茨海默病(AD)是困扰老年人的最常见的痴呆症类型,目前尚无治愈方法。?-分泌酶调节剂(GSMs)是一类很有前途的治疗阿尔茨海默病的药物。拟议的研究将为gsm如何起作用提供关键的见解,并可能最终导致改进阿尔茨海默病治疗方法。
英文摘要
DESCRIPTION (provided by applicant): Program Director/Principal Investigator (Last, First, Middle): Kukar, Thomas L. PROJECT SUMMARY (See instructions): Numerous lines of evidence support the hypothesis that selective targeting of A¿42 is an ideal therapeutic strategy to prevent and possibly treat Alzheimer's disease (AD), the major cause of dementia among the elderly. A class of compounds called ?-secretase modulators (GSMs) is being pursued as AD therapeutics because they are able to selectively alter A¿42 levels>. The first GSMs to be discovered were certain non- steroidal anti-inflammatory drugs (NSAIDs), which have been shown to selectively decrease A¿42 without global inhibition of APR processing. As whole GSMs minimally alter total Abeta production and instead shift the gamma-secretase cleavage site. The mechanism of GSMs has not been conclusively proven and different explanations for their activity have been proposed including: 1) allosteric binding to ?-secretase 2) inhibition of the Rho-ROCK signaling pathway 3) conformational changes in presenilin or 4) decreased dimerization of APR. We have recently discovered, using novel GSM photoaffinity probes, that these drugs do not label the y-secretase enzyme but instead modulate cleavage by binding to a the substrate, APP. We hypothesize that binding of APR by GSMs shifts the} position of APP-CTF in the membrane resulting in altered gamma-secretase cleavage. This hypothesis will be tested through the following specific aims: 1) investigate how substrate targeting by GSMs produces a shift in the cleavage pattern of A¿ using a combination of molecular biology and protein biochemistry 2) determine the specificity of GSMs for affecting APP proteolysis by ?-secretase in comparison to other substrates using mass spectrometry and 3) test if unnatural amino acids can be used to study proteolysis of APP-CTF¿ by ?-secretase. Aim 1 and career/technical training will take place during the mentored phase, which will facilitate the execution of Aims 2 and 3 during the independent phase. These studies should provide additional insight into the mechanisms whereby NSAIDs and other GSMs shift A¿ cleavage and how they exert their protective effects in vivo. This work will also guide future efforts to design more potent GSMs which will be useful as chemical probes for understanding the biology of ?-secretase and as potential therapeutics for Alzheimer's disease. RELEVANCE (See instructions): Alzheimer's disease (AD) is the most common type of dementia afflicting the elderly with no known cure. ?- secretase modulators (GSMs) are a promising class of drugs under investigation to treat AD. The proposed research will provide critical insight into how GSMs work and may ultimately lead to improved AD therapeutics.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Resolving the function of progranulin in lysosomal lipid metabolism and the etiology of Alzheimer's disease and frontotemporal dementia
-
批准号:10526035
-
项目类别:
-
资助金额:$209.81万
-
财政年份:2022
-
负责人:THOMAS L KUKAR
-
依托单位:
Molecular mechanisms of Progranulin in Neurodegeneration
-
批准号:9886298
-
项目类别:
-
资助金额:$38.59万
-
财政年份:2018
-
负责人:THOMAS L KUKAR
-
依托单位:
Molecular mechanisms of Progranulin in Neurodegeneration
-
批准号:10112970
-
项目类别:
-
资助金额:$38.55万
-
财政年份:2018
-
负责人:THOMAS L KUKAR
-
依托单位:
Molecular mechanisms of Progranulin in Neurodegeneration
-
批准号:10370343
-
项目类别:
-
资助金额:$38.5万
-
财政年份:2018
-
负责人:THOMAS L KUKAR
-
依托单位:
Defining the role of FUS phosphorylation in neurodegeneration
-
批准号:8946010
-
项目类别:
-
资助金额:$32.03万
-
财政年份:2015
-
负责人:THOMAS L KUKAR
-
依托单位:
Defining the role of FUS phosphorylation in neurodegeneration
-
批准号:9533703
-
项目类别:
-
资助金额:$32.22万
-
财政年份:2015
-
负责人:THOMAS L KUKAR
-
依托单位:
Defining the role of FUS phosphorylation in neurodegeneration
-
批准号:9115265
-
项目类别:
-
资助金额:$32.39万
-
财政年份:2015
-
负责人:THOMAS L KUKAR
-
依托单位:
Selective modulation of Gamma-secretase processing through substrate binding
-
批准号:8414480
-
项目类别:
-
资助金额:$24.85万
-
财政年份:2009
-
负责人:THOMAS L KUKAR
-
依托单位:
Selective modulation of Gamma-secretase processing through substrate binding
-
批准号:8416366
-
项目类别:
-
资助金额:$22.85万
-
财政年份:2009
-
负责人:THOMAS L KUKAR
-
依托单位:
Selective modulation of Gamma-secretase processing through substrate binding
-
批准号:8605484
-
项目类别:
-
资助金额:$23.65万
-
财政年份:2009
-
负责人:THOMAS L KUKAR
-
依托单位:
海外基金